ClinicalTrials.gg
RecruitingNCT07859488Updated Oct 5, 2026

Perioperative Biomarkers and Postoperative Delirium in Older Adults Undergoing Abdominal Cancer Surgery

An observational study in Postoperative Delirium (POD) and Abdominal Neoplasms, sponsored by Fatma Cigdem Ozakin. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Fatma Cigdem Ozakin · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Emergence Delirium with a site in Turkey — 28 open to participants now, 32 under way, none of them phase 3. Emergence Delirium · Turkey.

Planned enrollment
27th of 51
100 · median 110
Started
2026
with 27 others
Observational
51 of 92
14 open now
Primary completion
2027-09
later than 29 of 31 live
Registered
87th of 92
by date

Among the 92 studies in Emergence Delirium with a site in Turkey, this one is the 27th largest by planned enrollment of the 51 observational ones that give a count, is one of 28 that started in 2026, is one of 51 observational ones, reaches primary completion later than 29 of the 31 other live ones, and was the 87th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

28 of the 92 studies in Emergence Delirium with a site in Turkey are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Emergence Delirium with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational cohort study aims to investigate the relationship between perioperative endogenous melatonin levels and postoperative delirium in patients aged 65 years or older undergoing elective abdominal cancer surgery. The study will also evaluate serotonin, kynurenine, kynurenic acid, and vitamin B12 as potential biomarkers associated with postoperative delirium.

Participants will undergo routine standardized general anesthesia and thoracic epidural analgesia. Venous blood samples will be obtained preoperatively and on postoperative day 3. In participants who develop delirium, an additional blood sample will be obtained as soon as possible after delirium is detected. Postoperative delirium will be assessed using the Confusion Assessment Method (CAM) on postoperative days 1, 3, and 5. No experimental drug or additional therapeutic intervention will be administered as part of the study.

Read the detailed description

Postoperative delirium is an acute neurocognitive disorder that occurs frequently in older patients after major surgery. Neuroinflammation, alterations in neurotransmitter metabolism, oxidative stress, and disruption of circadian rhythm have been proposed as contributing mechanisms.

The primary objective of this prospective observational cohort study is to evaluate the relationship between perioperative endogenous melatonin levels and the development of postoperative delirium in patients aged 65 years or older undergoing elective abdominal surgery for malignancy. Secondary objectives include evaluation of serotonin, kynurenine, kynurenic acid, and vitamin B12 levels in relation to postoperative delirium.

Eligible participants will receive the routine standardized anesthesia and analgesia protocol used at the study center, including general anesthesia and thoracic epidural analgesia. No experimental drug or treatment will be administered.

Venous blood samples will be obtained during the preoperative period for measurement of melatonin, serotonin, kynurenine, kynurenic acid, and vitamin B12. These biomarkers will be measured again on postoperative day 3. In participants who develop postoperative delirium, an additional sample will be obtained as soon as possible after delirium is detected.

Intraoperative hemodynamic parameters, vasopressor requirements, cerebral oxygenation measured by near-infrared spectroscopy, depth of anesthesia measured by Bispectral Index, estimated blood loss, blood product transfusion, anesthesia duration, and surgical duration will also be recorded.

Postoperative delirium will be prospectively evaluated using the Confusion Assessment Method on postoperative days 1, 3, and 5. Participants will subsequently be classified as having or not having postoperative delirium, and perioperative biomarker levels and clinical variables will be compared between these groups.

03

Conditions studied

  • Postoperative Delirium (POD)
  • Abdominal Neoplasms

Keywords

  • Postoperative delirium
  • Melatonin
  • Serotonin
  • Kynurenine
  • Kynurenic acid
  • Vitamin B12
  • Neuroinflammation
  • Geriatric surgery
  • Abdominal cancer surgery
  • Confusion Assessment Method
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of patients aged 65 years or older who are scheduled for elective abdominal surgery for malignancy at Bakirkoy Dr. Sadi Konuk Research and Training Hospital and who meet the study eligibility criteria and provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older.
  • Scheduled for elective abdominal surgery for .
  • (ASA) physical status II or III.
  • Surgery planned under general anesthesia.
  • Eligible for thoracic epidural analgesia without to epidural catheter placement.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Preoperative dementia, Alzheimer disease, Parkinson disease, other known neurodegenerative disease, or a history of preoperative cognitive impairment.
  • Emergency surgery.
  • to epidural analgesia or refusal of epidural catheter placement.
  • Chronic use of , melatonin preparations, or medications affecting the serotonergic system, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, or tricyclic antidepressants.
  • Parenteral or high-dose oral vitamin B12 treatment within the previous 3 months.
  • Diagnosis of pernicious anemia.
  • Communication impairment preventing delirium assessment.
  • Advanced liver or kidney failure.
  • Intraoperative mean arterial pressure below 65 mmHg.
  • Surgical duration longer than 240 minutes.
  • Refusal to participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Older Adults Undergoing Elective Abdominal Cancer Surgery

    Patients aged 65 years or older undergoing elective abdominal surgery for malignancy under general anesthesia with thoracic epidural analgesia. All participants will be prospectively followed for postoperative delirium through postoperative day 5. Participants will not be assigned to treatment groups. For analysis, participants will be classified according to whether postoperative delirium develops based on CAM assessments.

    Diagnostic Test: Perioperative Biomarker Assessment · Diagnostic Test: Confusion Assessment Method (CAM)

Interventions

  • Diagnostic testPerioperative Biomarker Assessment

    Venous blood samples will be obtained preoperatively and on postoperative day 3 for measurement of melatonin, serotonin, kynurenine, kynurenic acid, and vitamin B12. In participants who develop postoperative delirium, an additional blood sample will be obtained as soon as possible after delirium is detected. Biomarker measurements will not be used to determine clinical treatment.

  • Diagnostic testConfusion Assessment Method (CAM)

    The Confusion Assessment Method will be used to assess delirium preoperatively and on postoperative days 1, 3, and 5. Postoperative delirium will be considered present if at least one postoperative CAM assessment is positive.

06

What researchers measure

Primary outcomes

  1. Change in Serum Melatonin Concentration From Preoperative Baseline to Postoperative Day 3 According to Postoperative Delirium Status

    Serum melatonin concentration will be measured preoperatively and on postoperative day 3. For each participant, the change in melatonin concentration will be calculated as the postoperative day 3 value minus the preoperative value and reported in pg/mL. Participants will be classified as having postoperative delirium if at least one CAM assessment on postoperative days 1, 3, or 5 is positive. The change in melatonin concentration will be compared between participants with and without postoperative delirium.

    Time frame: Preoperative baseline to postoperative day 3; postoperative delirium status assessed through postoperative day 5

  2. Number of Participants With Postoperative Delirium Assessed by the Confusion Assessment Method

    Postoperative delirium will be assessed using the Confusion Assessment Method (CAM) on postoperative days 1, 3, and 5. A participant will be classified as having postoperative delirium if any of these postoperative CAM assessments is positive. According to the CAM algorithm, delirium is present when acute onset and fluctuating course and inattention are present together with either disorganized thinking or an altered level of consciousness. The number and percentage of participants with postoperative delirium will be reported.

    Time frame: Postoperative day 1 through postoperative day 5

Secondary outcomes

  1. Change in Serum Serotonin Concentration From Preoperative Baseline to Postoperative Day 3 According to Postoperative Delirium Status

    Serum serotonin concentration will be measured preoperatively and on postoperative day 3. The change from the preoperative value will be calculated for each participant and compared between participants with and without postoperative delirium.

    Time frame: Preoperative baseline to postoperative day 3

  2. Change in Serum Kynurenine Concentration From Preoperative Baseline to Postoperative Day 3 According to Postoperative Delirium Status

    Serum kynurenine concentration will be measured preoperatively and on postoperative day 3. The change from the preoperative value will be calculated for each participant and compared between participants with and without postoperative delirium.

    Time frame: Preoperative baseline to postoperative day 3

  3. Change in Serum Kynurenic Acid Concentration From Preoperative Baseline to Postoperative Day 3 According to Postoperative Delirium Status

    Serum kynurenic acid concentration will be measured preoperatively and on postoperative day 3. The change from the preoperative value will be calculated for each participant and compared between participants with and without postoperative delirium.

    Time frame: Preoperative baseline to postoperative day 3

07

Study locations

1 of 1 sites recruiting
  • Bakırköy Dr. Sadi Konuk Training and Research Hospital
    Istanbul, Istanbul 34147, Turkey (Türkiye)
    Recruiting
    • Fatma Çiğdem Özakın, MD · Contactf.cigdemulus@gmail.com · +905464168250
    • Fidan Aygün, MD · Principal investigator
    • Fatma Çiğdem Özakın, MD · Sub investigator
    • Nilgün Işıksaçan, MD · Sub investigator
    • Mustafa Yaman, PhD · Sub investigator
08

References and documents

Publications

  • Elbakry AA, El-Desoky IM, Saafan AG, Elsersy HE. The impact of melatonin on postoperative delirium in geriatric patients after colorectal surgery: a randomized placebo-controlled trial. Minerva Anestesiol. 2024 Jun;90(6):509-519. doi: 10.23736/S0375-9393.24.17888-1. PubMed 38869264 ↗
  • Phing AH, Makpol S, Nasaruddin ML, Wan Zaidi WA, Ahmad NS, Embong H. Altered Tryptophan-Kynurenine Pathway in Delirium: A Review of the Current Literature. Int J Mol Sci. 2023 Mar 15;24(6):5580. doi: 10.3390/ijms24065580. PubMed 36982655 ↗
  • Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014 Mar 8;383(9920):911-22. doi: 10.1016/S0140-6736(13)60688-1. Epub 2013 Aug 28. PubMed 23992774 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 180 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 180 studies reached it within 21 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 5, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 6, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859488
Lead sponsor
Fatma Cigdem Ozakin
Responsible party
Fatma Cigdem Ozakin (MD, Bakirkoy Dr. Sadi Konuk Research and Training Hospital) — Sponsor-investigator
First posted
Oct 5, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 6, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Fidan Aygün, MD
Contact
fidanaygun1971@gmail.com
+90 505 400 2965
Fatma Çiğdem Özakın, MD
Contact
f.cigdemulus@gmail.com
+90 546 416 82 50
Fatma Çiğdem Özakın, MD
study director · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion